Publication
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerHead and Neck Squamous Cell Carcinomacivic_curation1.00
- drugErlotinibcivic_curation1.00
- geneMAPK1civic_curation1.00
- variantMAPK1 E322Kcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26181029
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| MAPK1 E278E1 | ||||||||
| Erlotinib | Head and Neck Squamous Cell Carcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4607A stage IVA head and neck squamous cell carcinoma patient with MAPK1 E322K mutation was reported to be sensitive to erlotinib treatment. The patient was treated with erlotinib monotherapy daily for 13… (full text at CIViC) PMID 26181029 · Van Allen et al., 2015 · Open in CIViC | civic |
| MAPK1 E322K1 | ||||||||
| Erlotinib | Head and Neck Squamous Cell Carcinoma | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID791Case report of a patient with stage IVA HNSCC with near-complete histologic response after 13 days of neoadjuvant erlotinib. Whole-exome sequencing of the pre-treatment tumor revealed a MAPK1 E322K mu… (full text at CIViC) PMID 26181029 · Van Allen et al., 2015 · Open in CIViC | civic |